AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22407256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated lenses with three 0.20 mm fenestrations at 120° intervals
Number of subjects: 22
Study 22407256 — intervention group
Group type: COMPARATOR
Intervention: Non-fenestrated lenses
Number of subjects: 22
Study 20510665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to beta-blocking agents
Number of subjects: 1037
Study 20510665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to folic acid
Number of subjects: 1037
Study 20510665 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation, antiemetics, analgesics, antibiotics, or any other main ATC group
Number of subjects: 1037
Study 18179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 2
Study 18179323 — intervention group
Group type: COMPARATOR
Intervention: Reappraisal
Number of subjects: 2
Study 16707912 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (433 +/- 40 pmol/l)
Number of subjects: 16
Study 16707912 — intervention group
Group type: COMPARATOR
Intervention: No insulin (serum insulin levels suppressed at 14 +/- 1 pmol/l)
Number of subjects: 16
Study 16707912 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 16
Study 16707912 — intervention group
Group type: COMPARATOR
Intervention: No insulin
Number of subjects: 16
Study 14629524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL 25% sucrose
Number of subjects: 128
Study 14629524 — intervention group
Group type: COMPARATOR
Intervention: 1 mL water (placebo)
Number of subjects: 128
Study 10797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estradiol-norethindrone (OC E+P)
Number of subjects: 8
Study 10797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-only oral contraceptive (OC P)
Number of subjects: 8
Study 10797125 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase
Number of subjects: 8
Study 10797125 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 8
Study 8890423 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm CO2 gas insufflation (group B, n = 53)
Number of subjects: 103
Study 8890423 — intervention group
Group type: COMPARATOR
Intervention: Cold CO2 gas insufflation (control group A, n = 50)
Number of subjects: 103
Study 1702696 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% dextran-60 in Ringer's lactate (D60)
Number of subjects: 20
Study 1702696 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 20
Study 6873133 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/d
Number of subjects: 10
Study 31258136 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth-containing quadruple therapy (BQT)
Number of subjects: 216
Study 31258136 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day bismuth-containing quadruple therapy (BQT)
Number of subjects: 216
Study 31258136 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day moxifloxacin-bismuth-combined treatment (MBCT)
Number of subjects: 216
Study 31258136 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day moxifloxacin-bismuth-combined treatment (MBCT)
Number of subjects: 216
Study 28900759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (SC)
Number of subjects: 101
Study 28900759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 27432383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with vonoprazan-amoxicillin-clarithromycin
Number of subjects: 24
Study 27432383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with vonoprazan-amoxicillin-metronidazole
Number of subjects: 24
Study 27432383 — intervention group
Group type: COMPARATOR
Intervention: Control (single therapy)
Number of subjects: 24
Study 27432383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 24
Study 24471366 — intervention group
Group type: EXPERIMENTAL
Intervention: Training offered and received
Number of subjects: 0
Study 24471366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered training)
Number of subjects: 0
Study 22892157 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN (2 g/day)
Number of subjects: 60
Study 22892157 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐OM3 (4 g/day)
Number of subjects: 60
Study 22892157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (ERN + P‐OM3)
Number of subjects: 60
Study 22892157 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 60
Study 20462054 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) plus chemotherapy
Number of subjects: 80
Study 20462054 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 80
Study 18260838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg
Number of subjects: 76
Study 18260838 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 76
Study 15778862 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 81
Study 15778862 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (twice-daily for 7 days)
Number of subjects: 81
Study 11835022 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 11835022 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 11835022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 0
Study 11835022 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin in addition to aspirin
Number of subjects: 0
Study 11835022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GP IIb/IIIa inhibitors
Number of subjects: 0
Study 12579695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh amniotic membrane transplantation (AMT)
Number of subjects: 39
Study 12579695 — intervention group
Group type: COMPARATOR
Intervention: Preserved amniotic membrane transplantation (AMT)
Number of subjects: 39
Study 12579695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh AMT
Number of subjects: 39
Study 12579695 — intervention group
Group type: COMPARATOR
Intervention: Preserved AMT
Number of subjects: 39
Study 8665975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 30
Study 8665975 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 30
Study 2087820 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine given after an early evening meal (6 p.m.)
Number of subjects: 279
Study 2087820 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ranitidine given at bedtime (10 p.m.)
Number of subjects: 279
Study 2087820 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine (early evening) for patients with ulcer diameter 5 mm to 9.5 mm and a history of duodenal ulcer
Number of subjects: 279
Study 467056 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper formulation of oral contraceptive
Number of subjects: 270
Study 467056 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet of oral contraceptive
Number of subjects: 270
Study 30303436 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13+QIV
Number of subjects: 882
Study 30303436 — intervention group
Group type: COMPARATOR
Intervention: Placebo+QIV
Number of subjects: 882
Study 30303436 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 882
Study 27348601 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO patients
Number of subjects: 72
Study 27348601 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 72
Study 27348601 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO patients under 75 years
Number of subjects: 72
Study 27348601 — intervention group
Group type: COMPARATOR
Intervention: Matched controls under 75 years
Number of subjects: 72
Study 25796058 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLA-TUM
Number of subjects: 92
Study 25796058 — intervention group
Group type: COMPARATOR
Intervention: SP-LM
Number of subjects: 92
Study 23541061 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS impregnated with bFGF at 7 or 14 μg/cm(2) after debridement
Number of subjects: 17
Study 23541061 — intervention group
Group type: COMPARATOR
Intervention: CGS impregnated with bFGF (low-dose group)
Number of subjects: 17
Study 23541061 — intervention group
Group type: COMPARATOR
Intervention: CGS impregnated with bFGF (high-dose group)
Number of subjects: 17
Study 23541061 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS impregnated with bFGF
Number of subjects: 17
Study 20647949 — intervention group
Group type: COMPARATOR
Intervention: PNF40
Number of subjects: 15
Study 20647949 — intervention group
Group type: COMPARATOR
Intervention: PNF60
Number of subjects: 15
Study 20647949 — intervention group
Group type: COMPARATOR
Intervention: PNF80
Number of subjects: 15
Study 22128425 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture after administration of aspirin 500 mg
Number of subjects: 14
Study 22128425 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture after administration of placebo
Number of subjects: 14
Study 17126656 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 54
Study 17126656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15051597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g DHA/d for 3 months
Number of subjects: 38
Study 11720771 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced gamma band responses (GBRs) during the recall sequence of the learning condition.
Number of subjects: 0
Study 11720771 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase synchrony between electrode sites during the recall sequence of the learning condition.
Number of subjects: 0
Study 8998089 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOU (chest pain observation unit)
Number of subjects: 104
Study 8998089 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient hospitalization
Number of subjects: 104
Study 8328365 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 480
Study 8328365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 3521843 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital sodium plus chlorpromazine (SC)
Number of subjects: 18
Study 3521843 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide, diphenhydramine, and dexamethasone (MDD)
Number of subjects: 18
Study 29047142 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (anti-EGFR)
Number of subjects: 400
Study 29047142 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (anti-VEGF)
Number of subjects: 400
Study 26933803 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine administration
Number of subjects: 50
Study 24914089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified care group (ICG)
Number of subjects: 74
Study 24914089 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (SCG)
Number of subjects: 74
Study 22801200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary surfactant by tracheal instillation during mechanical ventilation postoperatively
Number of subjects: 23
Study 22801200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pulmonary surfactant treatment)
Number of subjects: 23
Study 20536474 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream application alone
Number of subjects: 1020
Study 20536474 — intervention group
Group type: COMPARATOR
Intervention: Skin care
Number of subjects: 1020
Study 20536474 — intervention group
Group type: COMPARATOR
Intervention: Skin protection
Number of subjects: 1020
Study 20536474 — intervention group
Group type: COMPARATOR
Intervention: Both combined
Number of subjects: 1020
Study 20536474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1020
Study 18272338 — intervention group
Group type: EXPERIMENTAL
Intervention: Penrose rubber drain inserted into the extraction socket after surgery and left for 72 h
Number of subjects: 100
Study 18272338 — intervention group
Group type: COMPARATOR
Intervention: No rubber drain used (Control)
Number of subjects: 100
Study 15902851 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (8 cm incision)
Number of subjects: 60
Study 15902851 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (15 cm incision)
Number of subjects: 60
Study 14577892 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about recalled negative experiences (RNE group)
Number of subjects: 100
Study 14577892 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing about recalled negative experiences (RNE group)
Number of subjects: 100
Study 14577892 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing-and-writing about recalled negative experiences (RNE group)
Number of subjects: 100
Study 14577892 — intervention group
Group type: COMPARATOR
Intervention: Writing on neutral topics (NT group)
Number of subjects: 100
Study 14577892 — intervention group
Group type: COMPARATOR
Intervention: Drawing on neutral topics (NT group)
Number of subjects: 100
Study 14577892 — intervention group
Group type: COMPARATOR
Intervention: Drawing-and-writing on neutral topics (NT group)
Number of subjects: 100
Study 11083136 — intervention group
Group type: EXPERIMENTAL
Intervention: Early OC use (days 7-9)
Number of subjects: 10
Study 11083136 — intervention group
Group type: EXPERIMENTAL
Intervention: Late OC use (days 19-21)
Number of subjects: 10
Study 11083136 — intervention group
Group type: COMPARATOR
Intervention: Off OC use (days 2-4)
Number of subjects: 10
Study 9538713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane temperature using the Diatek 9000 InstaTemp thermometer
Number of subjects: 60
Study 9538713 — intervention group
Group type: EXPERIMENTAL
Intervention: Axilla temperature using the Tempa.DOT Ax chemical thermometer
Number of subjects: 60
Study 9538713 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery blood temperature (gold standard)
Number of subjects: 60
Study 9538713 — intervention group
Group type: COMPARATOR
Intervention: Fan therapy directed to the head
Number of subjects: 60
Study 8517426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 to 20 mg)
Number of subjects: 203
Study 8517426 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 203
Study 3525990 — intervention group
Group type: EXPERIMENTAL
Intervention: Beaded catheters
Number of subjects: 41
Study 3525990 — intervention group
Group type: COMPARATOR
Intervention: Unbeaded catheters
Number of subjects: 41
Study 30212861 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 176
Study 30212861 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 176
Study 27046619 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic simulation (stereo group)
Number of subjects: 20
Study 27046619 — intervention group
Group type: COMPARATOR
Intervention: Non-stereoscopic simulation (non-stereo group)
Number of subjects: 20
Study 26525387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-status e-confederates
Number of subjects: 304
Study 26525387 — intervention group
Group type: COMPARATOR
Intervention: Low-status e-confederates
Number of subjects: 304
Study 26525387 — intervention group
Group type: EXPERIMENTAL
Intervention: Public session
Number of subjects: 304
Study 26525387 — intervention group
Group type: EXPERIMENTAL
Intervention: Private session
Number of subjects: 304
Study 22935549 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion-time window 'on'
Number of subjects: 3
Study 22935549 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion-time window 'after'
Number of subjects: 3
Study 22935549 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion-time window 'before' to 'on'
Number of subjects: 3
Study 22935549 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion-time window 'on' to 'after'
Number of subjects: 3
Study 22935549 — intervention group
Group type: EXPERIMENTAL
Intervention: Including 'completion-time window' variable in the model
Number of subjects: 3
Study 20679548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arrest cooling with RhinoChill device
Number of subjects: 194
Study 20679548 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 194
Study 19378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.625 mg)
Number of subjects: 150
Study 19378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg)
Number of subjects: 150
Study 19378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 150
Study 19378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg)
Number of subjects: 150
Study 19378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 150
Study 19378542 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 150
Study 16831962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol, 0.014 mg/d (n = 208)
Number of subjects: 417
Study 16831962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 209)
Number of subjects: 417
Study 12716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (0.5%); administered at different times: before dissection, after dissection, or both.
Number of subjects: 66
Study 12716083 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline); no bupivacaine administered.
Number of subjects: 66
Study 11036134 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pouch reconstruction (DP group)
Number of subjects: 41
Study 11036134 — intervention group
Group type: COMPARATOR
Intervention: Single pouch reconstruction (SP group)
Number of subjects: 41
Study 8822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride (SR-NaF)
Number of subjects: 296
Study 8822339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 29498176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics training involving photography and self-assessment
Number of subjects: 135
Study 27679946 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm punch biopsy at two sites
Number of subjects: 105
Study 27679946 — intervention group
Group type: COMPARATOR
Intervention: 2-mm punch biopsy at one site
Number of subjects: 105
Study 25555673 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ training (5 hours of cholecystectomy training on cadaver organs)
Number of subjects: 30
Study 25555673 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality training (proficiency‐based cholecystectomy training on the LapMentor)
Number of subjects: 30
Study 25555673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 30
Study 23748514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 232
Study 23748514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 23748514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (clinical practice trial)
Number of subjects: 232
Study 21443793 — intervention group
Group type: EXPERIMENTAL
Intervention: 540,000 IU (corresponding to 13.5 mg) of cholecalciferol (VITD) dissolved in 45 ml herbal oil
Number of subjects: 25
Study 21443793 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 25
Study 18595013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pouch with preserved duodenal passage
Number of subjects: 28
Study 18595013 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch with preserved duodenal passage
Number of subjects: 28
Study 15777293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (40 mg)
Number of subjects: 122
Study 15777293 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (40 mg)
Number of subjects: 122
Study 15777293 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 122
Study 12067171 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenders (n=198)
Number of subjects: 236
Study 12067171 — intervention group
Group type: COMPARATOR
Intervention: Nonattenders (n=38)
Number of subjects: 236
Study 12080833 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin and Chinese traditional drug-Jiegudan
Number of subjects: 40
Study 12080833 — intervention group
Group type: COMPARATOR
Intervention: Jiegudan only (Control)
Number of subjects: 40
Study 8533580 — intervention group
Group type: EXPERIMENTAL
Intervention: DTcaP
Number of subjects: 905
Study 8533580 — intervention group
Group type: COMPARATOR
Intervention: DTaP
Number of subjects: 905
Study 1911606 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH administered by a nasal spray of 1 mg, four times daily, for 10 consecutive days starting on day 6 postpartum
Number of subjects: 19
Study 1911606 — intervention group
Group type: COMPARATOR
Intervention: Placebo sprays
Number of subjects: 19
Study 1911606 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH and Placebo
Number of subjects: 19
Study 7013058 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 4-8 years
Number of subjects: 23
Study 7013058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 23
Study 31512101 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunostomy feeding (JF)
Number of subjects: 120
Study 31512101 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric feeding (NF)
Number of subjects: 120
Study 30934747 — intervention group
Group type: EXPERIMENTAL
Intervention: Senatore Cappelli wheat variety pasta
Number of subjects: 42
Study 30934747 — intervention group
Group type: COMPARATOR
Intervention: Standard commercial pasta
Number of subjects: 42
Study 27775195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone suppositories (400 mg daily)
Number of subjects: 304
Study 27775195 — intervention group
Group type: COMPARATOR
Intervention: 17-alpha-hydroxyprogesterone caproate (17OHP-C) (250 mg i.m. once a week)
Number of subjects: 304
Study 27775195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (vaginal progesterone and 17OHP-C)
Number of subjects: 304